REG - Silence Therapeutics - Silence to Present at Jefferies London Conference

Silence TherapeuticsAnnouncement

11/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211111:nRSK0197Sa&default-theme=true

RNS Number : 0197S  Silence Therapeutics PLC  11 November 2021

 

Silence Therapeutics to Present at Jefferies London Healthcare Conference

 

 

11 November 2021

 

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the
Company"), a leader in the discovery, development and delivery of novel short
interfering ribonucleic acid (siRNA) therapeutics for the treatment of
diseases with significant unmet medical need, today announced that the Company
will present at the Jefferies London Healthcare Conference being held November
16-18, 2021.

The on-demand presentation will be available beginning on Thursday, November
18 at 8:00am GMT / 3:00am ET and can be accessed via the Investors section of
the Silence website at www.silence-therapeutics.com. An archived replay of the
webcast will be available on the Company's website following the conference.

 

 

Enquiries:

 

 Silence Therapeutics plc                               Tel:  +1 (646) 637-3208

 Gem Hopkins, Head of IR and Corporate Communications

 ir@silence-therapeutics.com

   Investec Bank plc (Nominated Adviser and Broker)       Tel:  +44 (0) 20 7597 5970

 Daniel Adams/Gary Clarence

 European PR                                            Tel: +44 (0) 20 3709 5700

 Consilium Strategic Communications

 Mary-Jane Elliott/ Angela Gray / Chris Welsh

 silencetherapeutics@consilium-comms.com

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing
the body's natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the pathology of
diseases with significant unmet need. Silence's proprietary mRNAi GOLD™
platform can be used to create siRNAs (short interfering RNAs) that precisely
target and silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates include
SLN360 designed to address the high and prevalent unmet medical need in
reducing cardiovascular risk in people born with high levels of lipoprotein(a)
and SLN124 designed to address iron-loading anemia conditions. Silence also
maintains ongoing research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit https://www.silence-therapeutics.com/
(https://www.silence-therapeutics.com/) .

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBMBBTMTBBTRB